TrialBlood2017

A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML.

Steven Knapper et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.